First dosing was Nov 11, 2015. At Rodman&Renshaw mid-Sept 2016, we were told BETonMACE was ~1/4 enrolled (0.25 X 2400 = 600 patients). So it took ~10 months to enroll the first ~600 patients (60 patients/month average for the 1st 600 patients). The NR 3/17/17 indicated that over 1200 patients have no been enrolled. So 16 months to ~1200 patients, but importantly only ~6 months to get the 2nd group of 600 (100 patients/month average for the 2nd 600 patients). We have ~9.5 months left in 2017 since that news release last week. If BETonMACE averages an enrollment of 125 patients/month for the next 9.5 months, then BETonMACE will be fully enrolled (2400 patients) by end of 2017.

At the 12/15/16 Corporate Update, they indicated that slower than expected recruitment rate triggered a clause with the contract research organization to bring in Russia (20 sites, 200 patients) as another country. This will be paid for by the contract research organization. Additionally, we were told at the Corporate Update that Taiwan will begin recruiting in Q1 2017. So the addition of Russia/Taiwan sites, (and possibly US sites?), could accelerate this recruitment even more.